Skip to Content

'
Samuel A. Shelburne, III, M.D., Ph.D.

Present Title & Affiliation

N/A

Office Address

Fax: 713-794-4351

Education & Training

Degree-Granting Education

2005 Baylor College of Medicine, Houston, TX, MS, Clinical Investigation
1998 University of Texas Medical Branch, Galveston, TX, MD, Medical Degree
1994 Princeton University, Princeton, NJ, AB, History of Art

Postgraduate Training

6/2002-5/2005 Clinical Fellowship, Infectious Diseases, Baylor College of Medicine, Houston, TX
7/2001-6/2002 Chief Resident, Baylor College of Medicine, Houston, TX
6/1998-6/2001 Clinical Internship, Internal Medicine, Baylor College of Medicine, Houston, TX
6/1998-6/2001 Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX

Board Certifications

2012 American Board of Internal Medicine
2004 American Board of Internal Medicine, Infectious Diseases

Experience/Service

Academic Appointments

Assistant Professor, Department of Infectious Diseases, Infection Control and Employee Health, Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 8/2008-9/2012

Honors and Awards

2005 Outstanding Research Award, Baylor College of Medicine
2000-2002 Baylor Graduate Medical Education Resident Teaching Award, Baylor College of Medicine
1999-2000 Outstanding Clinical Research Award, Baylor College of Medicine
1999-2000 Outstanding Resident Educator, Baylor College of Medicine

Selected Publications

Peer-Reviewed Original Research Articles

1. Shelburne SA, Olsen RJ, Makthal N, Brown NG, Sahasrabhojane P, Watkins EM, Palzkill T, Musser JM, Kumaraswami M. An N-Terminal Signal Peptide Of Vfr Protein Negatively Influences RopB-Dependent SpeB Expression and Attenuates Virulence in Streptococcus pyogenes. Mol Microbiol 82(6):1481-95, 12/2011. e-Pub 11/2011. PMID: 22040048.
2. Horstmann N, Sahasrabhojane P, Suber B, Kumaraswami M, Olsen RJ, Flores A, Musser JM, Brennan RG, Shelburne SA. Distinct single amino acid replacements in the control of virulence regulator protein differentially impact streptococcal pathogenesis. PLoS Pathog 7(10):e1002311, 10/2011. e-Pub 10/20/2011. PMCID: PMC3197619.
3. Shelburne SA, Sahasrobhajane P, Suber B, Keith DB, Davenport MT, Horstmann N, Kumaraswami M, Olsen RJ, Brennan RG, Musser JM. Niche-specific contribution to streptococcal virulence of a MalR-regulated carbohydrate binding protein. Mol Microbiol 81(2):500-14, 7/2011. e-Pub 6/5/2011. PMCID: PMC3147245.
4. Carroll RK, Shelburne SA, Olsen RJ, Suber B, Sahasrabhojane P, Kumaraswami M, Beres SB, Shea PR, Flores AR, Musser JM. Naturally occurring single amino acid replacements in a regulatory protein alter streptococcal gene expression and virulence in mice. J Clin Invest 121(5):1956-68, 5/2011. e-Pub 4/1/2011. PMCID: PMC3083769.
5. Kung DH, Hubenthal EA, Kwan JY, Shelburne SA, Goodman JC, Kass JS. Toxoplasmosis myelopathy and myopathy in an AIDS patient: a case of immune reconstitution inflammatory syndrome? Neurologist 17(1):49-51, 1/2011. PMID: 21192196.
6. Shelburne SA, Olsen RJ, Suber B, Sahasrabhojane P, Sumby P, Brennan RG, Musser JM. A combination of independent transcriptional regulators shapes bacterial virulence gene expression during infection. PLoS Pathog 6(3):e1000817, 3/2010. e-Pub 3/19/2010. PMCID: PMC2841617.
7. Shelburne SA, Keith DB, Davenport MT, Beres SB, Carroll RK, Musser JM. Contribution of AmyA, an extracellular alpha-glucan degrading enzyme, to group A streptococcal host-pathogen interaction. Mol Microbiol 74(1):159-74, 10/2009. e-Pub 9/2009. PMID: 19735442.
8. Treviño J, Perez N, Ramirez-Peña E, Liu Z, Shelburne SA, Musser JM, Sumby P. CovS simultaneously activates and inhibits the CovR-mediated repression of distinct subsets of group A Streptococcus virulence factor-encoding genes. Infect Immun 77(8):3141-9, 8/2009. e-Pub 5/18/2009. PMCID: PMC2715666.
9. Livorsi DJ, Daver NG, Atmar RL, Shelburne SA, White AC, Musher DM. Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA. J Infect 57(2):128-31, 8/2008. e-Pub 6/17/2008. PMID: 18562009.
10. Shelburne SA, Keith DB, Davenport MT, Horstmann N, Brennan RG, Musser JM. Molecular characterization of group A Streptococcus maltodextrin catabolism and its role in pharyngitis. Mol Microbiol 69(2):436-52, 7/2008. PMID: 18485073.
11. Shelburne SA, Keith D, Horstmann N, Sumby P, Davenport MT, Graviss EA, Brennan RG, Musser JM. A direct link between carbohydrate utilization and virulence in the major human pathogen group A Streptococcus. Proc Natl Acad Sci U S A 105(5):1698-1703, 2/2008. e-Pub 1/2008. PMCID: PMC2234207.
12. Shelburne SA, Singh KV, White AC, Byrne L, Carmer A, Austin C, Graviss E, Stager C, Murray BE, Atmar RL. Sequential outbreaks of infections by distinct Acinetobacter baumannii strains in a public teaching hospital in Houston, Texas. J Clin Microbiol 46(1):198-205, 1/2008. e-Pub 11/2007. PMCID: PMC2224270.
13. Daver NG, Shelburne SA, Atmar RL, Giordano TP, Stager CE, Reitman CA, White AC. Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis. J Infect 54(6):539-44, 6/2007. e-Pub 1/2007. PMID: 17198732.
14. Shelburne SA, Okorafor N, Sitkiewicz I, Sumby P, Keith D, Patel P, Austin C, Graviss EA, Musser JM. Regulation of polysaccharide utilization contributes to the persistence of group a streptococcus in the oropharynx. Infect Immun 75(6):2981-90, 6/2007. e-Pub 4/2007. PMCID: PMC1932865.
15. Shelburne SA, Fang H, Okorafor N, Sumby P, Sitkiewicz I, Keith D, Patel P, Austin C, Graviss EA, Musser JM, Chow DC. MalE of group A Streptococcus participates in the rapid transport of maltotriose and longer maltodextrins. J Bacteriol 189(7):2610-7, 4/2007. e-Pub 1/2007. PMCID: PMC1855798.
16. Shelburne SA, Greenberg SB, Aslam S, Tweardy DJ. Successful ceftriaxone therapy of endocarditis due to penicillin non-susceptible viridans streptococci. J Infect 54(2):e99-101, 2/2007. e-Pub 7/7/2006. PMID: 16824611.
17. Gonzalez BE, Rueda AM, Shelburne SA, Musher DM, Hamill RJ, Hulten KG. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect Control Hosp Epidemiol 27(10):1051-6, 10/2006. e-Pub 9/2006. PMID: 17006811.
18. Kaka AS, Rueda AM, Shelburne SA, Hulten K, Hamill RJ, Musher DM. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 58(3):680-3, 9/2006. e-Pub 7/2006. PMID: 16840428.
19. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 57(2):167-70, 2006. e-Pub 12/14/2005. PMID: 16354748.
20. Shelburne SA, Sumby P, Sitkiewicz I, Okorafor N, Granville C, Patel P, Voyich J, Hull R, DeLeo FR, Musser JM. Maltodextrin utilization plays a key role in the ability of group A Streptococcus to colonize the oropharynx. Infect Immun 74(8):4605-14, 2006. PMCID: PMC1539623.
21. Shelburne SA, Sumby P, Sitkiewicz I, Granville C, DeLeo FR, Musser JM. Central role of a bacterial two-component gene regulatory system of previously unknown function in pathogen persistence in human saliva. Proc Natl Acad Sci U S A 102(44):16037-42, 11/2005. e-Pub 10/2005. PMCID: PMC1276065.
22. Shelburne SA, Visnegarwala F, Adams C, Krause KL, Hamill RJ, White AC. Unusual manifestations of disseminated Histoplasmosis in patients responding to antiretroviral therapy. Am J Med 118(9):1038-41, 9/2005. PMID: 16164892.
23. Shelburne SA, Granville C, Tokuyama M, Sitkiewicz I, Patel P, Musser JM. Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva. Infect Immun 73(8):4723-31, 8/2005. PMCID: PMC1201272.
24. Shelburne SA, Darcourt J, White AC, Greenberg SB, Hamill RJ, Atmar RL, Visnegarwala F. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 40(7):1049-52, 4/2005. e-Pub 3/2005. PMID: 15825000.
25. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, Hamill RJ. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19(4):399-406, 3/2005. PMID: 15750393.
26. Shelburne SA, Musher DM, Hulten K, Ceasar H, Lu MY, Bhaila I, Hamill RJ. In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations. Antimicrob Agents Chemother 48(10):4016-9, 10/2004. PMCID: PMC521878.
27. Shelburne SA, Kielhofner MA, Tiwari PS. Cerebellar involvement in legionellosis. South Med J 97(1):61-4, 1/2004. PMID: 14746424.
28. Shelburne SA, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC, Visnegarwala F, Trautner BW. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81(3):213-27, 5/2002. PMID: 11997718.

Last updated: 3/21/2014